Study or Subgroup	PD-1/PD-L1i+chemotherapy Events	Total	chemotherapy Events	Total	Weight	Odds Ratio M-H, Fixed, 95% CI
1.4.1 Anemia						
GeparNuevo study 2019	2	92	2	82	0.6%	0.89 [0.12, 6.46]
I-SPY2 Trial 2020	5	69	10	181	1.5%	1.34 [0.44, 4.06]
IMpassion031 2020	14	164	12	167	3.3%	1.21 [0.54, 2.69]
KEYNOTE-522 2020	142	781	58	389	19.1%	1.27 [0.91, 1.77]
NeoTRIPaPDL1 2020	2	138	0	0		Not estimable
Subtotal (95% CI)		**1244**		**819**	**24.5%**	**1.25 [0.94, 1.68]**
Total events	165		82			
Heterogeneity: Chi² = 0.14, df = 3 (P = 0.99); I² = 0%						
Test for overall effect: Z = 1.52 (P = 0.13)						
1.4.2 Neutropenia						
GeparNuevo study 2019	34	92	34	82	6.8%	0.83 [0.45, 1.52]
I-SPY2 Trial 2020	7	69	2	181	0.3%	10.10 [2.04, 49.94]
IMpassion031 2020	38	164	36	167	8.2%	1.10 [0.65, 1.84]
KEYNOTE-522 2020	270	781	129	389	33.9%	1.06 [0.82, 1.38]
Subtotal (95% CI)		**1106**		**819**	**49.3%**	**1.09 [0.88, 1.35]**
Total events	349		201			
Heterogeneity: Chi² = 8.28, df = 3 (P = 0.04); I² = 64%						
Test for overall effect: Z = 0.82 (P = 0.41)						
1.4.3 Nausea						
GeparNuevo study 2019	0	92	7	82	2.4%	0.05 [0.00, 0.97]
I-SPY2 Trial 2020	4	69	0	181	0.1%	24.94 [1.32, 469.56]
IMpassion031 2020	2	164	7	167	2.1%	0.28 [0.06, 1.38]
KEYNOTE-522 2020	26	781	5	389	1.9%	2.64 [1.01, 6.94]
Subtotal (95% CI)		**1106**		**819**	**6.5%**	**1.21 [0.68, 2.15]**
Total events	32		19			
Heterogeneity: Chi² = 14.30, df = 3 (P = 0.003); I² = 79%						
Test for overall effect: Z = 0.64 (P = 0.52)						
1.4.4 Fatigue						
GeparNuevo study 2019	5	92	9	82	2.7%	0.47 [0.15, 1.45]
I-SPY2 Trial 2020	5	69	1	181	0.2%	14.06 [1.61, 122.66]
IMpassion031 2020	6	164	5	167	1.4%	1.23 [0.37, 4.11]
KEYNOTE-522 2020	27	781	6	389	2.3%	2.29 [0.94, 5.58]
Subtotal (95% CI)		**1106**		**819**	**6.6%**	**1.59 [0.93, 2.72]**
Total events	43		21			
Heterogeneity: Chi² = 9.17, df = 3 (P = 0.03); I² = 67%						
Test for overall effect: Z = 1.68 (P = 0.09)						
1.4.5 Diarrhea						
GeparNuevo study 2019	3	92	0	82	0.2%	6.45 [0.33, 126.81]
I-SPY2 Trial 2020	5	69	4	181	0.6%	3.46 [0.90, 13.28]
IMpassion031 2020	4	164	1	167	0.3%	4.15 [0.46, 37.53]
KEYNOTE-522 2020	17	781	5	389	2.0%	1.71 [0.63, 4.67]
Subtotal (95% CI)		**1106**		**819**	**3.0%**	**2.54 [1.21, 5.32]**
Total events	29		10			
Heterogeneity: Chi² = 1.37, df = 3 (P = 0.71); I² = 0%						
Test for overall effect: Z = 2.47 (P = 0.01)						
1.4.6 Vomiting						
GeparNuevo study 2019	1	92	1	82	0.3%	0.89 [0.05, 14.46]
I-SPY2 Trial 2020	1	69	0	181	0.1%	7.95 [0.32, 197.49]
IMpassion031 2020	2	164	1	167	0.3%	2.05 [0.18, 22.82]
KEYNOTE-522 2020	18	781	6	389	2.4%	1.51 [0.59, 3.82]
Subtotal (95% CI)		**1106**		**819**	**3.0%**	**1.67 [0.75, 3.71]**
Total events	22		8			
Heterogeneity: Chi² = 1.18, df = 3 (P = 0.76); I² = 0%						
Test for overall effect: Z = 1.26 (P = 0.21)						
1.4.7 Rash						
GeparNuevo study 2019	1	92	1	82	0.3%	0.89 [0.05, 14.46]
IMpassion031 2020	4	164	1	167	0.3%	4.15 [0.46, 37.53]
KEYNOTE-522 2020	7	781	1	389	0.4%	3.51 [0.43, 28.62]
Subtotal (95% CI)		**1037**		**638**	**1.0%**	**2.87 [0.79, 10.43]**
Total events	12		3			
Heterogeneity: Chi² = 0.82, df = 2 (P = 0.66); I² = 0%						
Test for overall effect: Z = 1.61 (P = 0.11)						
1.4.8 Peripheral neuropathy						
GeparNuevo study 2019	9	92	9	82	2.6%	0.88 [0.33, 2.33]
I-SPY2 Trial 2020	2	69	3	181	0.5%	1.77 [0.29, 10.83]
IMpassion031 2020	2	164	5	167	1.5%	0.40 [0.08, 2.09]
KEYNOTE-522 2020	15	781	4	389	1.6%	1.88 [0.62, 5.72]
Subtotal (95% CI)		**1106**		**819**	**6.1%**	**1.09 [0.60, 2.00]**
Total events	28		21			
Heterogeneity: Chi² = 2.81, df = 3 (P = 0.42); I² = 0%						
Test for overall effect: Z = 0.29 (P = 0.77)						
Total (95% CI)		**8917**		**6371**	**100.0%**	**1.25 [1.08, 1.45]**
Total events	680		365			
Heterogeneity: Chi² = 45.53, df = 30 (P = 0.03); I² = 34%						
Test for overall effect: Z = 3.04 (P = 0.002)						
Test for subgroup differences: Chi² = 8.13, df = 7 (P = 0.32), I² = 13.9%						



eFigure 2.